ANIK Anika Therapeutics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 898437 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY52.5%
TTM net income YoY94.7%
TTM EPS YoY94.3%
Revenue 3-yr CAGR-8.9%
Net income 3-yr CAGR—
Margins
Gross margin63.4%
Operating margin-2.1%
Net margin-1.4%
FCF margin1.9%
EBITDA margin2.5%
Returns
ROE-1.2%
ROA-0.9%
ROIC (approx.)-2.3%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets27.4%
Debt / equity0.00x
Current ratio3.86x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-4.24x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue4.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $112.82M | $119.91M |
| Cost of revenue | $49.01M | $43.91M |
| Gross profit | $63.81M | $76.00M |
| R&D expense | $25.77M | $25.54M |
| SG&A expense | $49.09M | $55.55M |
| Operating income | -$11.05M | -$5.10M |
| Pretax income | -$9.31M | -$2.76M |
| Income tax | $672,000 | $6.06M |
| Net income | -$10.88M | -$56.38M |
| EBITDA | -$5.68M | $1.78M |
| EPS (basic) | -0.76 | -3.83 |
| EPS (diluted) | -0.76 | -3.83 |
| Weighted avg. shares (diluted) | 14.34M | 14.72M |
| Balance sheet | ||
| Cash & equivalents | $57.48M | $55.63M |
| Short-term investments | $23.69M | $23.59M |
| Receivables | $23.69M | $23.59M |
| Inventory | $18.79M | $23.81M |
| Current assets | $103.36M | $113.65M |
| PP&E, net | $40.32M | $38.99M |
| Goodwill | $8.05M | $7.12M |
| Intangibles | $1.65M | $2.49M |
| Total assets | $190.27M | $202.74M |
| Current liabilities | $21.91M | $23.31M |
| Total liabilities | $46.80M | $48.75M |
| Shareholders' equity | $143.47M | $153.99M |
| Shares outstanding | 13.89M | 14.42M |
| Cash flow statement | ||
| Operating cash flow | $11.19M | $5.40M |
| Capital expenditure | $6.83M | $7.73M |
| Free cash flow | $4.36M | -$2.33M |
| Investing cash flow | -$401,000 | -$8.33M |
| Financing cash flow | -$10.55M | -$12.73M |
| Depreciation & amortization | $5.37M | $6.88M |
| Stock-based compensation | $10.08M | $13.13M |
| Share buybacks | $9.48M | $10.91M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.